1. Home
  2. NMIH vs NUVB Comparison

NMIH vs NUVB Comparison

Compare NMIH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NMI Holdings Inc.

NMIH

NMI Holdings Inc.

HOLD

Current Price

$39.89

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.74

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMIH
NUVB
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.9B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
NMIH
NUVB
Price
$39.89
$5.74
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$42.60
$11.44
AVG Volume (30 Days)
459.9K
4.2M
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
11.06
N/A
EPS
4.92
N/A
Revenue
$706,440,000.00
N/A
Revenue This Year
N/A
$659.84
Revenue Next Year
$4.34
$180.43
P/E Ratio
$8.08
N/A
Revenue Growth
8.52
N/A
52 Week Low
$32.71
$1.57
52 Week High
$43.20
$9.75

Technical Indicators

Market Signals
Indicator
NMIH
NUVB
Relative Strength Index (RSI) 52.75 46.80
Support Level $36.84 $5.12
Resistance Level $39.96 $6.22
Average True Range (ATR) 1.00 0.34
MACD -0.05 0.08
Stochastic Oscillator 40.87 58.93

Price Performance

Historical Comparison
NMIH
NUVB

About NMIH NMI Holdings Inc.

NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: